New IRBM Contribution to the Journal of Pharmaceutical and Biomedical Analysis

DNA IRBM
DNA IRBM

New IRBM Contribution to the Journal of Pharmaceutical and Biomedical Analysis

IRBM researchers, led by Dr. Edith Monteagudo, have published a novel method to assess metabolism at the injection site of subcutaneously administered therapeutic peptides. Click on the link below to visit the article’s page on ScienceDirect.

A liquid chromatography high-resolution mass spectrometry in vitro assay to assess metabolism at the injection site of subcutaneously administered therapeutic peptides.

Redazione IRBM

Related Posts

Series of Novel and Highly Potent Cyclic Peptide PCSK9 Inhibitors Derived from an mRNA Display Screen and Optimized via Structure-Based Design
In the last few years macrocyclic peptides have emerged as a better class of lead candidates for inhibition of protein-protein interactions with respect to conventional small molecules. The IRBM peptide chemistry team collaborated with the teams at Merck & co. and RaPharma to develop potent macrocyclic peptide inhibitors of PCSK9 a key regulator of plasma LDL-cholesterol.
Back To Top